katherine trial: t-dm1 cuts her2-positve invasive breast cancer recurrence
Published 5 years ago • 2.9K plays • Length 2:02Download video MP4
Download video MP3
Similar videos
-
1:21
katherine trial tests trastuzumab emtansine in breast cancer recurrence
-
3:07
breast cancer drug t-dm1 shows promise in trial
-
4:19
asco: new treatment (t-dm1) for her2-positive advanced breast cancer?
-
6:04
katherine trial updates for her2-positive breast cancer
-
6:13
cleopatra: success with dual her2 blockade in breast cancer
-
3:21
breast cancer drug - trastuzumab emtansine - mechanism of action
-
5:05
anti-her2 mechanisms of approved her2 inhibitors
-
2:04
breast cancer chess championship: trastuzumab vs her2 receptor
-
4:06
her2 patients may do fine with local therapies alone
-
1:36
phase 3 trial investigates t-dm1 and pertuzumab in her2 breast cancer
-
1:18
expert discusses practice-changing data from katherine trial in breast cancer
-
1:38
t-dm1 plus pertuzumab in the marianne trial
-
5:15
case review: t-dm1 for residual her2 breast cancer
-
1:18
dr. hamilton discusses the katherine trial in her2 breast cancer
-
6:53
treating early her2 breast cancer: katherine
-
3:00
genes may predict trastuzumab outcomes in breast cancer
-
1:56
dr. rimawi discusses katherine trial in her2 breast cancer
-
4:52
emilia trial: t-dm1 in metastatic breast cancer
-
1:31
dr. geyer on the rationale for the katherine trial in her2-positive breast cancer
-
1:07
dr. tripathy discusses impact of t-dm1 in her2 breast cancer
-
1:29
dr. hamilton on the results of the katherine trial in her2 breast cancer
-
3:55
onc-chat: dr. martine piccart, 'absolutely no advantage' to 2 years of trastuzumab